Bioinformatics Group Leader

We are seeking a highly motivated, independent scientist to lead an effort to apply large scale gene expression analysis to assess the impact of genetic context on drug response using AVEO’s proprietary inducible tumor models. The position requires a PhD in Biology, Bioinformatics or equivalent, as well as 2+ years postdoctoral experience.  The ideal candidate has significant additional experience, including a proven track record of generating, processing and evaluating large oncology related datasets.  The desired candidate possesses a working knowledge of cancer biology, including an understanding of molecular mechanisms of cellular transformation.  Knowledge of statistical approaches to expression datasets as well as familiarity with software programming is preferred.

AVEO’s translational research program

AVEO has created a novel platform based on next generation inducible tumor models to discover, validate and generate therapeutics against molecular targets in oncology.  Furthermore, we have adapted our platform to generate large populations of genetically engineered tumors that exhibit inter-tumor variation similar to that seen in human tumor populations. Each tumor has been characterized by expression profiling, array CGH, histology and key signaling pathways.  Having developed methodology to archive these tumors, we have now generated data on the efficacy of targeted inhibitors across these populations, including AVEO’s clinical stage drug candidates, enabling the correlation of gene expression and DNA copy number with drug efficacy. 

This well characterized tumor population model system provides an attractive platform for the creative innovative bioinformatics scientist to develop and test translational hypotheses, with the goal of using the models to inform clinical trial design regarding tumor, tumor subtype and patient selection for AVEO’s own clinical stage oncology drug candidates.

About AVEO

 

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics.  AVEO’s proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets.  This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF), as well as collaborations with Merck, OSI Pharmaceuticals and Schering-Plough.  Through a combination of internal drug discovery and selective in-licensing of targeted therapeutics, AVEO is building a diversified product pipeline and moving toward its vision of becoming a fully integrated biopharmaceutical company. For more information, please visit the company's website at www.aveopharma.com

 

AVEO is an Equal Employment Opportunity employer that values the strength diversity brings to the workplace.

 

Please forward resumes to hr@aveopharma.com